Hydrogen sulphide - Is it an important, apart from nitric oxide and carbon oxide, gaseous transmitter in human;Siarkowodór - Czy jest ważnym, oprócz tlenku azotu i tlenku wȩgla, transmiterem gazowym u człowieka

Nadcisnienie Tetnicze

Volumn 16, Issue 2, 2012, Pages 120-124

  Kokot, Franciszek ^a   Hyla Klekot, Lidia ^b   Ficek, Rafał ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Chorzowskie Centrum Pediatrii i Onkologii   (Poland)

Author keywords

Carbon oxide; Hydrogen sulphide; Nitric oxide

Indexed keywords

CARBON MONOXIDE; HYDROGEN SULFIDE; NITRIC OXIDE;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; ENERGY METABOLISM; HUMAN; INFLAMMATION; NEUROPATHY; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; REVIEW;

EID: 84867385126     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Kabil O., Baneryce R. Redox biochemistry of hydrogen sulfide. J. Biol. Chem. 2010; 285: 21 903-21 907.
2. Perna A.F., Ingrosso D. Low hydrogen sulphide and chronic kidney disease: a dangerous liaison. Nephrol. Dial. Transplant. 2012; 27: 486-493.
3. Li L., Hsu A., Moore P.K. Actions and interactions of nitric oxide, carbon monooxide and hydrogen sulphide in the cardiovascular system and in inflammation - a tale of three gases. Pharmacology and Therapeutics 2009; 121: 386-400.
4. 2S by cystathionin-beta-synthase via the condensation of cysteine and homocysteine. J. Biol. Chem. 2004; 279: 52 082-52 086.
5. Whiterman M., Moose P.K. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability. J. Cell. Mol. Med. 2009; 13: 488-507.
6. Kimura G.A., Squadrito G.L., Mills R.W. i wsp. Hydrogen sulfide its production, release and function. Amino Acids 2011; 41: 113-123.
7. Benavides G.A., Squadrito G.L., Mills R.W. i wsp. Hydrogen sulfide mediates the vasoactivity of garlic. Proc. Natl. Acad. Sci USA 2007; 107: 17 977-17 982.
8. Kamoun P. Endogeneous production of hydrogen sulfide in normals. Amino Acids 2004; 26: 243-254. (Pubitemid 38829787)
9. Olson K.R. Is hydrogen sulfide a circulating gasotransmitter in vertebrate blood? Biochim. Biophys. Acta 2009; 1787: 856-863.
10. Bucci M., Papapetropoulos A., Vellecco V. i wsp. Hydrogen sulfide is an indogenous inhibitor of phosphodiesterase activity. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 1998-2004.
11. Meng C.H., Yang G., Yang W. i wsp. Protective effect of hydrogen sulfide on balloon injury induced neointima hyperplasia in rat carotid arteries. Am. J. Pathol. 2009; 170: 1406-1414. (Pubitemid 47339347)
12. 2S a stinky remedy for atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 2009; 29: 156-157.
13. Yang G., Wu L., Bryan S. i wsp. Cystathionine gammalyase deficiency and over-proliferation of smooth-muscle cells. Cardiovasc. Res. 2010; 86: 487-495.
14. Papapetropoulosa A., Pyriochoua A., Altaanyb Z. i wsp. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl. Acad. Sci. USA 2009; 106: 21 972-21 977.
15. Wang R. Signaling pathways for the vascular effects of hydrogen sulfide. Curr. Opin. Nephrol. Hypertens. 2011; 20: 107-112.
16. - donor NaHS releases nitric oxide fom nitrosothiols, metal nitrosyl complex, brain homogenate and murine L1210 leukaemia cells. Plügers Arch. Europ. J. Physiol. 2008; 457: 271-279.
17. ATP channels. Antioxid Redox Signal. 2010; 12: 1167-1178.
18. 2S signals through protein S-sulfhydration. Sci. Signal 2009; 2: ra72.
19. Wang R. Hydrogen sulfide: a new EDRF. Kidney Int. 2009; 16: 700-704.
20. 2+ signalling in human vascular endothelial cells by hydrogen sulfide. Atherosclerosis 2010; 209: 374-380.
21. Qiao W., Chuoshu T., Hongfang J. i wsp. Endogenous hydrogen sulfide is involved in the pathogenesis of atherosclerosis. Biochemical and Biophysical Research Communication 2010; 396: 182-186.
22. Li L., Moore P.K. Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends in Pharmacological Sciences. 2008; 29: 84-90.
23. Zhong G.Z., Chen F.R., Cheng Y.Q. i wsp. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by induction of nitric oxide synthase. J. Hypertens. 2003; 21: 1879-1895.
24. Sen U., Mishra P.K., Tyagi N. i wsp. Homocysteine to hydrogen sulfide or hypertension. Cell. Biochem. Biophys. 2010; 57: 49-58.
25. Wallace J.L. Hydrogen sulfide - releasing antiinflammatory drugs. Trends Pharmacol. Sc. 2007; 28: 501-505. (Pubitemid 47488507)
26. Mei Z., Qiang Z., Xiao-qin S.H.I. i wsp. Erythrocytic or serum hydrogen sulfide association with hypertension development in untreated essential hypertension. Chin. M.J. 2011; 124: 3693-3701.
27. Lu M., Liu Y.-H., Goh H.S. i wsp. Hydrogen sulfide inhibits plasma renin activity. J. Am. Soc. Nephrol. 2010; 21: 993-1002.
28. Yan H., Du J., Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochemical and Biophysical Research Communication 2004; 313: 22-27. (Pubitemid 37524019)
29. Perna A.F., Ingrosso D., Violetti E. i wsp. Hyperhomocysteinemia in uraemia - a red flag in a disrupted circuit. Seminars in Dialysis 2009; 22: 351-356.
30. Zavaczki E., Jeney V., Agarval A. i wsp. Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int. 2011; 80: 731-739.
31. Zhong G.Z. Hydrogen sulfide - a potent multichannel antiarrhythmic drug. J. Cardiovascular Dis. Res. 2010; 1: 17-39.
32. Bos E.M., Henri G.D., Snider P.M. i wsp. Hydrogen sulfide - induced hypometabolism prevents renal-ischemia reperfusion injury. J. Am. Soc. Nephrol. 2009; 20: 1901-1905.
33. 2S) producing enzymes and capacity in chronic kidney disease. Nephrol. Dial. Transplant. 2012; 27: 498-504.
34. Perna A.F., Sepe I., Lanza D. i wsp. Hydrogen sulfide increases after a single haemodialysis session. Kidney Int. 2011; 80: 1108-1109.
35. Sen U., Munjal C., Qipshidze N. i wsp. Hydrogen sulfide regulates homocysteine - mediated glomerulosclerosis. Am. J. Nephrol. 2010; 31: 442-455.
36. Perna A.F., Luciano M.G., Ingrosso D. i wsp. Hydrogen sulphide generating pathways in haemodialysis patients: a study on relevant metabolites and transcription regulation of genes incoding for key enzymes. Nephrol. Dial. Transplant. 2009; 24: 3756-3763.
37. Francescato H.C., Cunha F., Costa R.S. i wsp. Inhibition of hydrogen sulphide formation reduces cisplatin-induced renal damage. Nephrol. Dial. Hypertens. 2011; 26: 474-488.
38. Frendo J., Wrobel M. The activity of 3-mercaptopyruvate sulfurtransferase in erythrocystes from patients with polycythemia vera. Acta Biochemica Polona 1997; 44: 771-773.
39. Szabo C. Hydrogen sulphide and its therapeutic potential. Nature Reviews. Drug Discovery 2007; 6: 917-935. (Pubitemid 350042399)